Shattuck Labs, Inc. is a clinical stage biotechnology company that focuses on discovering and developing monoclonal and bispecific antibodies designed to block the Death Receptor 3 pathway for the treatment of inflammatory and immune mediated diseases. The company's lead candidate SL-325 is a high affinity monoclonal antibody engineered to inhibit the interaction between DR3 and its ligand TL1A. Shattuck Labs, Inc. is also advancing SL-425, a half life extended version of SL-325, and a pipeline of DR3 based bispecific antibodies that co-target DR3 with other validated immune mediators. These therapeutic candidates are intended for the treatment of inflammatory and immune mediated diseases, with initial clinical focus on inflammatory bowel disease including Crohn's disease and ulcerative colitis. The company leverages its expertise in protein engineering and tumor necrosis factor receptor biology to create molecules that aim to provide more complete and durable pathway blockade compared with existing TL1A directed therapies.

As a clinical stage entity Shattuck Labs, Inc. does not currently generate revenue from product sales. The company finances its research and development activities through equity financings, collaboration agreements and government or foundation grants. Strategic collaborations with larger biopharmaceutical partners may provide upfront payments, milestone reimbursements and royalty arrangements that contribute to operating cash flow. Additionally, proceeds from public and private offerings of its common stock support ongoing operations and pipeline advancement. The company manages its cash resources to advance clinical trials, manufacture drug substance and sustain general and administrative functions.

Shattuck Labs, Inc. positions itself as a pioneer in DR3 directed therapy while competing with several firms developing TL1A blocking antibodies for inflammatory bowel disease. Notable competitors include duvakitug from Teva, afimkibart from Roche, SPY002 and SPY072 from Spyre Therapeutics, tulisokibart from Merck, XmAb942 from Xencor and an antibody program from Abbvie and FutureGen (known as the Abbvie/FutureGen candidate). The company differentiates itself by targeting the receptor DR3 rather than the ligand TL1A, which may allow a more complete and durable blockade of the signaling axis. Because DR3 is stably expressed on lymphocytes, blockade may be maintained with less frequent dosing and may reduce the risk of antidrug antibody formation associated with immune complex formation seen in TL1A directed agents. This approach is expected to yield a favorable immunogenicity profile and may enable combination with other therapies without the concern of immune complex mediated clearance. Overall, Shattuck Labs, Inc. believes its mechanistic advantages could translate into improved efficacy and better long term outcomes for patients with immune mediated disorders.

The company intends to serve patients suffering from inflammatory bowel disease, specifically those with Crohn's disease and ulcerative colitis. Beyond IBD, Shattuck Labs, Inc. aims to develop therapies for other immune mediated conditions such as hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis, asthma and multiple sclerosis where the DR3/TL1A axis plays a role. The target audience includes gastroenterologists, dermatologists, rheumatologists and other specialists who manage chronic inflammatory diseases. Additionally, healthcare payors, including government programs and private insurers, will be important customers for reimbursement and formulary placement. Ultimately, the company seeks to provide therapeutic options that address unmet medical needs and improve quality of life for individuals with chronic immune mediated illnesses.